Search

Your search keyword '"Xu, Rui-Hua"' showing total 1,620 results
Start Over Author "Xu, Rui-Hua"
1,620 results on '"Xu, Rui-Hua"'

2. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

Author

Wang, Feng, Shen, Lin, Guo, Weijian, Liu, Tianshu, Li, Jin, Qin, Shukui, Bai, Yuxian, Chen, Zhendong, Wang, Jufeng, Pan, Yueyin, Shu, Yongqian, Zhao, Fuyou, Cheng, Ying, Ye, Feng, Gu, Kangsheng, Zhang, Tao, Pan, Hongming, Zhong, Haijun, Zhou, Fuxiang, Qin, Yanru, Yang, Lei, Mao, Weidong, Li, Qiu, Dai, Wenxiang, Li, Wei, Wang, Shubin, Tang, Yong, Ma, Dong, Yin, Xianli, Deng, Yanhong, Yuan, Ying, Li, Man, Hu, Wenwei, Chen, Donghui, Li, Guoxin, Liu, Qiqi, Tan, Panfeng, Fan, Songhua, Shi, Michael, Su, Weiguo, and Xu, Rui-Hua

Published
2024
Full Text
View/download PDF

3. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Author

Kitagawa, Yuko, Matsuda, Satoru, Gotoda, Takuji, Kato, Ken, Wijnhoven, Bas, Lordick, Florian, Bhandari, Pradeep, Kawakubo, Hirofumi, Kodera, Yasuhiro, Terashima, Masanori, Muro, Kei, Takeuchi, Hiroya, Mansfield, Paul F., Kurokawa, Yukinori, So, Jimmy, Mönig, Stefan Paul, Shitara, Kohei, Rha, Sun Young, Janjigian, Yelena, Takahari, Daisuke, Chau, Ian, Sharma, Prateek, Ji, Jiafu, de Manzoni, Giovanni, Nilsson, Magnus, Kassab, Paulo, Hofstetter, Wayne L., Smyth, Elizabeth Catherine, Lorenzen, Sylvie, Doki, Yuichiro, Law, Simon, Oh, Do-Youn, Ho, Khek Yu, Koike, Tomoyuki, Shen, Lin, van Hillegersberg, Richard, Kawakami, Hisato, Xu, Rui-Hua, Wainberg, Zev, Yahagi, Naohisa, Lee, Yeong Yeh, Singh, Rajvinder, Ryu, Min-Hee, Ishihara, Ryu, Xiao, Zili, Kusano, Chika, Grabsch, Heike Irmgard, Hara, Hiroki, Mukaisho, Ken-ichi, Makino, Tomoki, Kanda, Mitsuro, Booka, Eisuke, Suzuki, Sho, Hatta, Waku, Kato, Motohiko, Maekawa, Akira, Kawazoe, Akihito, Yamamoto, Shun, Nakayama, Izuma, Narita, Yukiya, Yang, Han-Kwang, Yoshida, Masahiro, and Sano, Takeshi

Published
2024
Full Text
View/download PDF

4. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial

Author

Wang, Feng, Jin, Ying, Wang, Min, Luo, Hui-Yan, Fang, Wei-Jia, Wang, Ying-Nan, Chen, Yan-Xing, Huang, Run-Jie, Guan, Wen-Long, Li, Ji-Bin, Li, Yu-Hong, Wang, Feng-Hua, Hu, Xiao-Hua, Zhang, Yan-Qiao, Qiu, Miao-Zhen, Liu, Lu-Lu, Wang, Zi-Xian, Ren, Chao, Wang, De-Shen, Zhang, Dong-Sheng, Wang, Zhi-Qiang, Liao, Wen-Ting, Tian, Lin, Zhao, Qi, and Xu, Rui-Hua

Published
2024
Full Text
View/download PDF

7. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial

Author

Yuan, Shu-Qiang, Nie, Run-Cong, Jin, Ying, Liang, Cheng-Cai, Li, Yuan-Fang, Jian, Rui, Sun, Xiao-Wei, Chen, Ying-Bo, Guan, Wen-Long, Wang, Zi-Xian, Qiu, Hai-Bo, Wang, Wei, Chen, Shi, Zhang, Dong-Sheng, Ling, Yi-Hong, Xi, Shao-Yan, Cai, Mu-Yan, Huang, Chun-Yu, Yang, Qiu-Xia, Liu, Zhi-Min, Guan, Yuan-Xiang, Chen, Yong-Ming, Li, Ji-Bin, Tang, Xiong-Wen, Peng, Jun-Sheng, Zhou, Zhi-Wei, Xu, Rui-Hua, and Wang, Feng

Published
2024
Full Text
View/download PDF

8. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

Author

Wang, De-Shen, Ren, Chao, Li, Shan-Shan, Fong, William Pat, Wu, Xiao-Jun, Xiao, Jian, Li, Bin-Kui, Zheng, Yun, Ding, Pei-Rong, Chen, Gong, Qiu, Miao-Zhen, Wang, Zhi-Qiang, Wang, Feng-Hua, Luo, Hui-Yan, Wang, Feng, Wang, Xiao-Zhong, Wang, Ling-Yun, Xie, De-Jin, Chen, Tao, Li, Li-Ren, Lu, Zhen-Hai, Zhai, Xiao-Hui, Liu, Tian-Shu, Yuan, Ying, Chen, Jia-Qi, Tan, Qiong, Pan, Zhi-Zhong, Wan, De-Sen, Zhang, Rong, Yuan, Yun-Fei, Xu, Rui-Hua, and Li, Yu-Hong

Subjects
Metastasis -- Physiological aspects, Pharmacology, Experimental, Colorectal cancer -- Drug therapy -- Physiological aspects, Drug therapy, Combination -- Testing -- Physiological aspects, Cancer -- Care and treatment -- Chemotherapy, Chemotherapy -- Testing -- Physiological aspects, Liver cancer -- Drug therapy -- Physiological aspects, Biological sciences
Abstract

Background It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with unresectable CRLM. Methods and findings This open-label, randomized clinical trial was conducted from April 2018 to December 2022 in 7 medical centers across China, enrolling 146 RAS/BRAF wild-type CRC patients with initially unresectable CRLM. A stratified blocked randomization method was utilized to assign patients (1:1) to either the cetuximab plus FOLFOXIRI (n = 72) or cetuximab plus FOLFOX (n = 74) treatment arms. Stratification factors were tumor location (left versus right) and resectability (technically unresectable versus [greater than or equal to]5 metastases). The primary outcome was the objective response rate (ORR). Secondary outcomes included the median depth of tumor response (DpR), early tumor shrinkage (ETS), R0 resection rate, progression-free survival (PFS), overall survival (not mature at the time of analysis), and safety profile. Radiological tumor evaluations were conducted by radiologists blinded to the group allocation. Primary efficacy analyses were conducted based on the intention-to-treat population, while safety analyses were performed on patients who received at least 1 line of chemotherapy. A total of 14 patients (9.6%) were lost to follow-up (9 in the doublet arm and 5 in the triplet arm). The ORR was comparable following adjustment for stratification factors, with 84.7% versus 79.7% in the triplet and doublet arms, respectively (odds ratio [OR] 0.70; 95% confidence intervals [CI] [0.30, 1.67], Chi-square p = 0.42). Moreover, the ETS rate showed no significant difference between the triplet and doublet arms (80.6% (58/72) versus 77.0% (57/74), OR 0.82, 95% CI [0.37, 1.83], Chi-square p = 0.63). Although median DpR was higher in the triplet therapy group (59.6%, interquartile range [IQR], [50.0, 69.7] versus 55.0%, IQR [42.8, 63.8], Mann-Whitney p = 0.039), the R0/R1 resection rate with or without radiofrequency ablation/stereotactic body radiation therapy was comparable with 54.2% (39/72) of patients in the triplet arm versus 52.7% (39/74) in the doublet arm. At a median follow-up of 26.2 months (IQR [12.8, 40.5]), the median PFS was 11.8 months in the triplet arm versus 13.4 months in the doublet arm (hazard ratio [HR] 0.74, 95% CI [0.50, 1.11], Log-rank p = 0.14). Grade [greater than or equal to] 3 events were reported in 47.2% (35/74) of patients in the doublet arm and 55.9% (38/68) of patients in the triplet arm. The triplet arm was associated with a higher incidence of grade [greater than or equal to] 3 neutropenia (44.1% versus 27.0%, p = 0.03) and diarrhea (5.9% versus 0%, p = 0.03). The primary limitations of the study encompass the inherent bias in subjective surgical decisions regarding resection feasibility, as well as the lack of a centralized assessment for ORR and resection. Conclusions The combination of cetuximab with FOLFOXIRI did not significantly improve ORR compared to cetuximab plus FOLFOX. Despite achieving an enhanced DpR, this improvement did not translate into improved R0 resection rates or PFS. Moreover, the triplet arm was associated with an increase in treatment-related toxicity. Trial Registration ClinicalTrials.gov Identifier: NCT03493048., Author(s): De-Shen Wang 1, Chao Ren 1, Shan-Shan Li 2, William Pat Fong 1, Xiao-Jun Wu 3, Jian Xiao 2,4, Bin-Kui Li 5, Yun Zheng 5, Pei-Rong Ding 3, Gong [...]

Published
2024
Full Text
View/download PDF

9. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial

Author

He, Mingming, Wang, Zhiqiang, Lu, Jin, Bai, Yuxian, Mao, Teng, Wang, Jun, Fan, Qingxia, Zhang, Yiping, Zhao, Kuaile, Chen, Zhendong, Gao, Shegan, Li, Jiancheng, Fu, Zhichao, Gu, Kangsheng, Liu, Zhihua, Wu, Lin, Zhang, Xiaodong, Feng, Jifeng, Niu, Zuoxing, Ba, Yi, Zhang, Helong, Liu, Ying, Zhang, Li, Min, Xuhong, Huang, Jing, Cheng, Ying, Wang, Dong, Sheng, Zhen, Zeng, Wanqin, Song, Li, Xu, Rui-Hua, and Luo, Huiyan

Published
2024
Full Text
View/download PDF

13. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Author

Shah, Manish A., Shitara, Kohei, Ajani, Jaffer A., Bang, Yung-Jue, Enzinger, Peter, Ilson, David, Lordick, Florian, Van Cutsem, Eric, Gallego Plazas, Javier, Huang, Jing, Shen, Lin, Oh, Sang Cheul, Sunpaweravong, Patrapim, Soo Hoo, Hwoei Fen, Turk, Haci Mehmet, Oh, Mok, Park, Jung Wook, Moran, Diarmuid, Bhattacharya, Pranob, Arozullah, Ahsan, and Xu, Rui-Hua

Published
2023
Full Text
View/download PDF

14. Survival influence of gender on 42,345 patients with gastric cardia adenocarcinoma

Author

Xu, Rui Hua, Zhao, Xue Ke, Song, Xin, Lei, Ling Ling, Zhong, Kan, Han, Wen Li, Wang, Ran, De Bao, Qi, Hu, Jing Feng, Wei, Meng Xia, Ji, Jia Jia, Li, Liu Yu, Fan, Zong Min, Han, Xue Na, Li, Bei, Yang, Yuan Ze, Sun, Lin, Li, Jia, Yang, Miao Miao, Li, Xing Song, You, Duo, Bai, He Lin, Qiao, Jia Xin, Xie, Ye Zhen, Zhou, Fu You, Li, Xue Min, Li, Ai Li, and Wang, Li Dong

Published
2023
Full Text
View/download PDF

28. Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial

Author

Yuan, Shu-Qiang, Nie, Run-Cong, Jin, Ying, Liang, Cheng-Cai, Li, Yuan-Fang, Jian, Rui, Sun, Xiao-Wei, Chen, Ying-Bo, Guan, Wen-Long, Wang, Zi-Xian, Qiu, Hai-Bo, Wang, Wei, Chen, Shi, Zhang, Dong-Sheng, Ling, Yi-Hong, Xi, Shao-Yan, Cai, Mu-Yan, Huang, Chun-Yu, Yang, Qiu-Xia, Liu, Zhi-Min, Guan, Yuan-Xiang, Chen, Yong-Ming, Li, Ji-Bin, Tang, Xiong-Wen, Peng, Jun-Sheng, Zhou, Zhi-Wei, Xu, Rui-Hua, and Wang, Feng

Published
2024
Full Text
View/download PDF

29. Extended virtual detector theory including quantum interferences

Author

Xu, Rui-Hua, Wang, Xu, and Eberly, J. H.

Subjects
Physics - Atomic Physics, Physics - Computational Physics
Abstract

We extend our earlier "virtual detector" method [X. Wang, J. Tian, and J. H. Eberly, Phys. Rev. Lett. 110, 243001 (2013)], a hybrid quantum mechanical and classical trajectory method, to include phases in the classical trajectories. Effects of quantum interferences, lost in the earlier method, are restored. The obtained photoelectron momentum distributions agree well with the corresponding numerical solutions of the time-dependent Schr\"odinger equation.

Published
2020
Full Text
View/download PDF

35. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Author

Shitara, Kohei, Lordick, Florian, Bang, Yung-Jue, Enzinger, Peter, Ilson, David, Shah, Manish A, Van Cutsem, Eric, Xu, Rui-Hua, Aprile, Giuseppe, Xu, Jianming, Chao, Joseph, Pazo-Cid, Roberto, Kang, Yoon-Koo, Yang, Jianning, Moran, Diarmuid, Bhattacharya, Pranob, Arozullah, Ahsan, Park, Jung Wook, Oh, Mok, and Ajani, Jaffer A

Published
2023
Full Text
View/download PDF

38. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study

Author

Shah, Manish A., Yoshino, Takayuki, Tebbutt, Niall C., Grothey, Axel, Tabernero, Josep, Xu, Rui-Hua, Cervantes, Andres, Oh, Sang Cheul, Yamaguchi, Kensei, Fakih, Marwan, Falcone, Alfredo, Wu, Christina, Chiu, Vi K., Tomasek, Jiri, Bendell, Johanna, Fontaine, Marilyn, Hitron, Matthew, Xu, Bo, Taieb, Julien, and Van Cutsem, Eric

Published
2023
Full Text
View/download PDF

41. Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.

Author

Liu, Sai Lan, primary, Mai, Hai-Qiang, additional, Wen, Dongxiang, additional, Yang, Jin-Hao, additional, Guo, Shan-Shan, additional, Liu, Li-Ting, additional, Luo, Mei-Juan, additional, Liang, YuJing, additional, Sun, Xue-Song, additional, Li, Xiao-Yun, additional, Luo, Dong-Hua, additional, Li, Ji-Bin, additional, Wang, Pan, additional, Guo, Ling, additional, Mo, Hao-Yuan, additional, Sun, Rui, additional, Zhao, Chong, additional, Xu, Rui-Hua, additional, Tang, Lin-Quan, additional, and Chen, Qiu-Yan, additional

Published
2024
Full Text
View/download PDF

42. Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.

Author

Xu, Rui-Hua, primary, Wang, Feng, additional, Chen, Gong, additional, Qiu, Meng, additional, Ma, Jinfeng, additional, Liu, Haiyi, additional, Mo, Xianwei, additional, Li, Yongqiang, additional, Wan, Xiangbin, additional, Luo, Jia, additional, Hu, Yingbin, additional, Huang, Xiwen, additional, Jiang, Weiqin, additional, Li, Leping, additional, Zhou, Yanbing, additional, Lu, Xiaoxiao, additional, Chen, Yuling, additional, Guo, Qun, additional, Li, Li, additional, and Zhou, Hui, additional

Published
2024
Full Text
View/download PDF

43. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Author

Qiu, Miao-Zhen, primary, Oh, Do-Youn, additional, Kato, Ken, additional, Arkenau, Tobias, additional, Tabernero, Josep, additional, Correa, Marcia Cruz, additional, Zimina, Anastasia V, additional, Bai, Yuxian, additional, Shi, Jianhua, additional, Lee, Keun-Wook, additional, Wang, Jufeng, additional, Poddubskaya, Elena, additional, Pan, Hongming, additional, Rha, Sun Young, additional, Zhang, Ruixing, additional, Hirano, Hidekazu, additional, Spigel, David, additional, Yamaguchi, Kensei, additional, Chao, Yee, additional, Wyrwicz, Lucjan, additional, Disel, Umut, additional, Cid, Roberto Pazo, additional, Fornaro, Lorenzo, additional, Evesque, Ludovic, additional, Wang, Hongwei, additional, Xu, Yaling, additional, Li, Jiang, additional, Sheng, Tao, additional, Yang, Silu, additional, Li, Liyun, additional, Moehler, Markus, additional, and Xu, Rui-Hua, additional

Published
2024
Full Text
View/download PDF

45. 3D RoI-aware U-Net for Accurate and Efficient Colorectal Tumor Segmentation

Author

Huang, Yi-Jie, Dou, Qi, Wang, Zi-Xian, Liu, Li-Zhi, Jin, Ying, Li, Chao-Feng, Wang, Lisheng, Chen, Hao, and Xu, Rui-Hua

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

Segmentation of colorectal cancerous regions from 3D Magnetic Resonance (MR) images is a crucial procedure for radiotherapy which conventionally requires accurate delineation of tumour boundaries at an expense of labor, time and reproducibility. While deep learning based methods serve good baselines in 3D image segmentation tasks, small applicable patch size limits effective receptive field and degrades segmentation performance. In addition, Regions of interest (RoIs) localization from large whole volume 3D images serves as a preceding operation that brings about multiple benefits in terms of speed, target completeness, reduction of false positives. Distinct from sliding window or non-joint localization-segmentation based models, we propose a novel multitask framework referred to as 3D RoI-aware U-Net (3D RU-Net), for RoI localization and in-region segmentation where the two tasks share one backbone encoder network. With the region proposals from the encoder, we crop multi-level RoI in-region features from the encoder to form a GPU memory-efficient decoder for detailpreserving segmentation and therefore enlarged applicable volume size and effective receptive field. To effectively train the model, we designed a Dice formulated loss function for the global-to-local multi-task learning procedure. Based on the efficiency gains, we went on to ensemble models with different receptive fields to achieve even higher performance costing minor extra computational expensiveness. Extensive experiments were conducted on 64 cancerous cases with a four-fold cross-validation, and the results showed significant superiority in terms of accuracy and efficiency over conventional frameworks. In conclusion, the proposed method has a huge potential for extension to other 3D object segmentation tasks from medical images due to its inherent generalizability. The code for the proposed method is publicly available., Comment: IEEE transactions on cybernetics (2020)

Published
2018
Full Text
View/download PDF

49. Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer

Author

Zhao, Qi, Wang, Feng, Chen, Yan-Xing, Chen, Shifu, Yao, Yi-Chen, Zeng, Zhao-Lei, Jiang, Teng-Jia, Wang, Ying-Nan, Wu, Chen-Yi, Jing, Ying, Huang, You-Sheng, Zhang, Jing, Wang, Zi-Xian, He, Ming-Ming, Pu, Heng-Ying, Mai, Zong-Jiong, Wu, Qi-Nian, Long, Renwen, Zhang, Xiaoni, Huang, Tanxiao, Xu, Mingyan, Qiu, Miao-Zheng, Luo, Hui-Yan, Li, Yu-Hong, Zhang, Dong-Shen, Jia, Wei-Hua, Chen, Gong, Ding, Pei-Rong, Li, Li-Ren, Lu, Zheng-Hai, Pan, Zhi-Zhong, and Xu, Rui-Hua

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results